BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 22191780)

  • 1. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage.
    Rosenholm JM; Mamaeva V; Sahlgren C; Lindén M
    Nanomedicine (Lond); 2012 Jan; 7(1):111-20. PubMed ID: 22191780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities & challenges.
    Rosenholm JM; Sahlgren C; Lindén M
    Nanoscale; 2010 Oct; 2(10):1870-83. PubMed ID: 20730166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesoporous silica nanoparticles in medicine--recent advances.
    Mamaeva V; Sahlgren C; Lindén M
    Adv Drug Deliv Rev; 2013 May; 65(5):689-702. PubMed ID: 22921598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesoporous silica nanoparticles for intracellular controlled drug delivery.
    Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS
    Small; 2010 Sep; 6(18):1952-67. PubMed ID: 20690133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyvalent nucleic acid/mesoporous silica nanoparticle conjugates: dual stimuli-responsive vehicles for intracellular drug delivery.
    Chen C; Geng J; Pu F; Yang X; Ren J; Qu X
    Angew Chem Int Ed Engl; 2011 Jan; 50(4):882-6. PubMed ID: 21246683
    [No Abstract]   [Full Text] [Related]  

  • 6. Functionalized mesoporous silica materials for controlled drug delivery.
    Yang P; Gai S; Lin J
    Chem Soc Rev; 2012 May; 41(9):3679-98. PubMed ID: 22441299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-based nanoparticles for cancer targeting.
    Sá LT; Simmons S; Missailidis S; da Silva MI; Santos-Oliveira R
    J Drug Target; 2013 May; 21(5):427-34. PubMed ID: 23350808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells.
    Liu HM; Wu SH; Lu CW; Yao M; Hsiao JK; Hung Y; Lin YS; Mou CY; Yang CS; Huang DM; Chen YC
    Small; 2008 May; 4(5):619-26. PubMed ID: 18491363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice.
    Liu T; Li L; Teng X; Huang X; Liu H; Chen D; Ren J; He J; Tang F
    Biomaterials; 2011 Feb; 32(6):1657-68. PubMed ID: 21093905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesoporous silica nanoparticles in nanotechnology.
    Douroumis D; Onyesom I; Maniruzzaman M; Mitchell J
    Crit Rev Biotechnol; 2013 Sep; 33(3):229-45. PubMed ID: 22724458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
    Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular degradation of multilabeled poly(ethylene imine)-mesoporous silica-silica nanoparticles: implications for drug release.
    Bergman L; Kankaanpää P; Tiitta S; Duchanoy A; Li L; Heino J; Lindén M
    Mol Pharm; 2013 May; 10(5):1795-803. PubMed ID: 23510188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesoporous silica nanoparticles as nanocarriers.
    Wu SH; Hung Y; Mou CY
    Chem Commun (Camb); 2011 Sep; 47(36):9972-85. PubMed ID: 21716992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pH-operated nanopistons on the surfaces of mesoporous silica nanoparticles.
    Zhao YL; Li Z; Kabehie S; Botros YY; Stoddart JF; Zink JI
    J Am Chem Soc; 2010 Sep; 132(37):13016-25. PubMed ID: 20799689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs.
    Lu J; Liong M; Zink JI; Tamanoi F
    Small; 2007 Aug; 3(8):1341-6. PubMed ID: 17566138
    [No Abstract]   [Full Text] [Related]  

  • 16. Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers.
    Popat A; Hartono SB; Stahr F; Liu J; Qiao SZ; Qing Max Lu G
    Nanoscale; 2011 Jul; 3(7):2801-18. PubMed ID: 21547299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
    She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
    Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
    Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
    Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
    Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
    Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional mesoporous silica nanoparticles for photothermal-controlled drug delivery in vivo.
    Yan H; Teh C; Sreejith S; Zhu L; Kwok A; Fang W; Ma X; Nguyen KT; Korzh V; Zhao Y
    Angew Chem Int Ed Engl; 2012 Aug; 51(33):8373-7. PubMed ID: 22777795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.